IGF1 Generation Test
Phase 4
Completed
- Conditions
- Growth Hormone Deficiency
- Registration Number
- NCT00145457
- Lead Sponsor
- Pfizer
- Brief Summary
To assess the predictive value of the short term IGF-1 stimulation test, based on IGF-1 changes, on the 24 months growth response to 2 different doses of GH in patients with conventional GH deficiency.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 82
Inclusion Criteria
- Male or female aged of more than 4 years.
- GHD defined as a peak GH level < 20 mUI/ml at two different pharmacological GH provocative tests including one done with two pharmacological agents and both performed within the year before the inclusion, according to the current recommendations of the French Health Authorities
Exclusion Criteria
- Previous treatment with GH
- Ongoing pharmacological treatment with steroids except if corresponding to substitutive therapy
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Change of height standard deviation score after 24 months of treatment according to the short term response of plasma IGF1 to Genotonorm.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Pfizer Investigational Site
🇫🇷Toulouse Cedex 9, France